$PKI (PerkinElmer Inc.)

$PKI {{ '2015-06-22T18:19:15+0000' | timeago}} • SEC

$PKI 1Q15 10-Q: As of April 30, 2015, PKI had 113,193,707 outstanding shares. As of March 29, 2015, 7.4MM shares remained available for repurchase from 8MM shares authorized by BoD under the Repurchase Program. In 1Q15, PKI repurchased 85,739 shares of common stock at an aggregate cost of $4MM.

$PKI {{ '2017-07-24T21:21:06+0000' | timeago}} • Announcement

$PKI BoD declared a regular quarterly dividend of $0.07 per share of common stock on July 24, 2017. This dividend is payable on Nov. 10, 2017 to all shareholders of record at the close of business on Oct. 20, 2017.

$PKI {{ '2017-06-19T12:54:47+0000' | timeago}} • Announcement

$PKI agreed to buy Euroimmun Medical Laboratory Diagnostics AG for about $1.3Bil in cash. The transaction is expected to close in 4Q17. The acquisition is expected to be accretive to $PKI's 2018 non-GAAP EPS by about $0.28-0.30. Also, $PKI is reaffirming its 2017 revenue and EPS guidance.

$PKI {{ '2017-05-04T20:54:11+0000' | timeago}} • Announcement

For FY17, $PKI expects GAAP EPS from continuing operations to be in the range of $2.16-2.28. On a non-GAAP basis, $PKI expects EPS to be in the range of $2.80-2.90.

$PKI {{ '2017-05-04T20:53:46+0000' | timeago}} • Announcement

During 1Q17, revenue from $PKI's Discovery & Analytical Solutions segment rose 1% rise in revenue to $361.8MM. Revenue from Diagnostics segment rose 8% YoY to $152.4MM.

$PKI {{ '2017-05-04T20:45:39+0000' | timeago}} • Announcement

Diagnostic tool maker $PKI's 1Q17 net income fell to $38.6MM, or $0.33 per share, compared to $47.4MM, or $0.38 per share during 1Q16. Revenue rose 3% YoY to $514Bil. Excluding items, $PKI earned $0.55 per share.

$VREX {{ '2017-05-01T21:40:24+0000' | timeago}} • Announcement

$VREX has completed the previously announced acquisition of the Medical Imaging business of $PKI for $276MM in cash, subject to post-closing adjustments. This acquisition is expected to add approx $140MM in annual sales to Varex.

$PKI {{ '2017-05-01T21:25:20+0000' | timeago}} • Announcement

$PKI said it completed the $276MM sale of its medical imaging business to $VREX. The sale was announced on December 22, 2016.

$PKI {{ '2017-04-28T20:43:22+0000' | timeago}} • Announcement

The Board of Directors of $PKI declared a regular quarterly dividend of $0.07 per share of common stock, payable on August 10, 2017 to all shareholders of record on July 21, 2017.

$PKI {{ '2017-04-05T12:55:32+0000' | timeago}} • Announcement

$PKI said novel research results of phase 1 clinical trial examines safety of using cord blood stem cells for treating children with Autism Spectrum Disorder (ASD). ASD is the name for a group of developmental disorders. ASD includes social, communication, and behavioral challenges. These problems can be mild, severe, or somewhere in between.

$PKI {{ '2017-02-02T21:51:03+0000' | timeago}} • Announcement

$PKI expects 2017 GAAP EPS from continuing operations of $2.06-2.16 and adjusted EPS of $2.75-2.85. CEO Robert Friel said $PKI has undertaken substantial steps to strengthen the organization, accelerate operational capabilities and increase focus on innovation, that better position it to improve revenue growth and lift profitability.

$PKI {{ '2017-02-02T21:49:07+0000' | timeago}} • Announcement

$PKI announced the divestiture of its Medical Imaging business in 4Q16. With the announcement, the company has moved the operating results of that business into discontinued operations thereby impacting comparability to previously issued financial guidance.

$PKI {{ '2017-02-02T21:48:53+0000' | timeago}} • Announcement

$PKI reported a decline in 4Q16 earnings due to higher income tax provision. Net income slid to $64.85MM or $0.59 per share from $68.25MM or $0.61 per share last year. Revenue declined to $566.77MM from $569.9MM. Adjusted EPS increased to $0.83 from $0.81.

$PKI {{ '2017-01-30T11:45:30+0000' | timeago}} • Announcement

$PKI's BoD declared a regular quarterly dividend of $0.07 per share of common stock. The dividend is payable on May 10, 2017 to all shareholders of record on April 14, 2017.

$PKI {{ '2017-01-09T21:38:22+0000' | timeago}} • Announcement

$PKI has entered into a definitive agreement to acquire Tulip Diagnostics Private Ltd. Based in Goa, India, Tulip is one of the largest domestic providers of in-vitro diagnostic reagents, kits and instruments to diagnostic labs and government and private healthcare facilities. The transaction is currently anticipated to close in 1Q17.

$PKI {{ '2016-12-22T13:42:12+0000' | timeago}} • Announcement

$PKI plans to sell its Medical Imaging business, a supplier of flat panel X-ray detectors that serve as components for industrial, medical and dental X-ray imaging systems, to $VAR. The transaction is expected to close in 1H17. CEO Robert Friel said the divestiture will allow $PKI to focus investments and accelerate growth in higher priority areas.

$VAR {{ '2016-12-22T13:25:00+0000' | timeago}} • Announcement

$VAR said it agreed to acquire the Medical Imaging business of $PKI as an addition to its Imaging Components business, for $276MM, which is slated to become an independent public company, Varex Imaging Corporation. The separation is expected to be complete in Jan. 2017.

$PKI {{ '2016-11-07T23:45:15+0000' | timeago}} • Webcast

$PKI stated that share repurchase would be determined considering the acquisition opportunities and the availability of shares. $PKI would acquire companies that add value and the company is actively looking at acquisitions that could close in the coming quarters.

$PKI {{ '2016-11-07T23:24:56+0000' | timeago}} • Webcast

From 4Q16, $PKI will report segment results as Diagnostics and Discovery and Analytical Solutions (DAS). Until 3Q16, the company reported its division results as Human Health segment and Enviornmental Health segment.

$PKI {{ '2016-11-07T23:10:40+0000' | timeago}} • Webcast

$PKI believes that its new product introductions this year will generate an incremental $40MM in revenue. The company widened its 4Q16 revenue guidance to $610-620MM, representing low-single digit organic revenue growth and adjusted EPS of $0.85-0.87.

$PKI {{ '2016-11-07T22:58:47+0000' | timeago}} • Webcast

$PKI reported that 3Q16 revenue performance was hurt by the additional week in the third quarter last year. Also, significant headwinds in radiochemical, medical imaging and environmental health businesses affected the results, the company said.

Recent Transcripts

WAT (Waters Corporation)
Tuesday, July 25 2017 - 12:00pm
ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
WOR (Worthington Industries, Inc.)
Thursday, June 29 2017 - 2:30pm
UQM (UQM Technologies Inc.)
Thursday, May 11 2017 - 8:30pm
COHR (Coherent Inc.)
Tuesday, May 9 2017 - 8:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
XRAY (DENTSPLY International Inc.)
Tuesday, May 9 2017 - 12:30pm
CVU (CPI Aerostructures Inc.)
Tuesday, May 9 2017 - 12:30pm
FLDM (Fluidigm Corporation)
Thursday, May 4 2017 - 9:00pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 9:00pm
PKI (PerkinElmer Inc.)
Thursday, May 4 2017 - 9:00pm
PSDV (pSivida Corp.)
Thursday, May 4 2017 - 8:30pm
CBMX (CombiMatrix Corporation)
Thursday, May 4 2017 - 8:30pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 12:00pm
MASI (Masimo Corporation)
Wednesday, May 3 2017 - 8:30pm
LBY (Libbey Inc.)
Tuesday, May 2 2017 - 3:00pm
XYL (Xylem Inc.)
Tuesday, May 2 2017 - 1:00pm
STS (Supreme Industries Inc.)
Monday, May 1 2017 - 1:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, April 28 2017 - 12:30pm
ROP (Roper Technologies, Inc.)
Friday, April 28 2017 - 12:30pm

AlphaGraphics you may like